Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
huMAb OX40L · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| huMAb OX40L | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| huMAb OX40L | DRUG | Intravenous repeating dose |
| placebo | DRUG | Intravenous repeating dose |
Inclusion Criteria: * Weight between 50 and 125 kg * Mild, stable allergic asthma * History of episodic wheeze and shortness of breath * FEV1 at baseline ≥ 70% of the predicted value * For women of childbearing potential, agreement to use an effective means of contraception while enrolled in the st...
huMAb OX40L is an investigational drug being studied for the prevention of allergen-induced airway obstruction in adults with mild allergic asthma. It is being developed by Roche Holding AG (RHHBY) and is currently in Phase 2 clinical development, though it is not yet approved.
huMAb OX40L targets the OX40 ligand, a protein involved in immune responses. By blocking this target, the drug aims to prevent allergen-induced airway obstruction in patients with mild allergic asthma. This mechanism is being evaluated in a Phase 2 clinical trial.
huMAb OX40L is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker RHHBY. The drug is currently in Phase 2 clinical development for the treatment of asthma.
huMAb OX40L is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its potential to prevent allergen-induced airway obstruction in adults with mild allergic asthma.
huMAb OX40L has one completed Phase 2 clinical trial, identified as NCT00983658. This study, titled 'A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma,' enrolled 29 participants and was a randomized, double-blind, placebo-controlled trial.
huMAb OX40L is a monoclonal antibody that targets OX40L, but it is not the same as other OX40L antibodies. It is a specific investigational drug developed by Roche. The drug is being studied for asthma and is currently in Phase 2 clinical trials.